Subscribe
2020-09-21
21 September 2020AmericasMuireann Bolger

LSPN Connect: Challenges in the US patent landscape

Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda
22 October 2019   While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.
Americas
LSPN 19: Mayo has led us down the rabbit hole, says lawyer
26 April 2019   There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.
Biotechnology
LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101
28 October 2020   Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda
22 October 2019   While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.
Americas
LSPN 19: Mayo has led us down the rabbit hole, says lawyer
26 April 2019   There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.
Biotechnology
LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101
28 October 2020   Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.

More on this story

Americas
LSPN 19: PTAB and ‘languishing’ STRONGER Act on 2020 agenda
22 October 2019   While the next Alice or Mayo is unlikely to be handed down next year, there are many slightly less “revolutionary" developments likely to crop up in 2020, according to Charles Larsen, partner at White & Case.
Americas
LSPN 19: Mayo has led us down the rabbit hole, says lawyer
26 April 2019   There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.
Biotechnology
LSPN Connect: Eldora Ellison on PTAB denials, CRISPR and section 101
28 October 2020   Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York